0.305

3.28% 0.00

Cara Therapeutics Inc (CARA)

Overview News Price History Option Chain Financials Why CARA Down? Discussions Forecast Stock Split

Cara Therapeutics Inc stock is traded at $0.305, with a volume of 57,754. It is up +3.28% in the last 24 hours and up +18.60% over the past month. Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Previous Close:

$0.305

Open:

$0.3019

24h Volume:

57,754

Relative Volume:

0.12

Market Cap:

$17.11M

Revenue:

$20.97M

Net Income/Loss:

$-118.51M

P/E Ratio:

-0.1481

EPS:

-2.06

Net Cash Flow:

$-94.45M

1W Performance:

-3.85%

1M Performance:

+18.60%

6M Performance:

-58.21%

1Y Performance:

-68.81%

1-Day Range:

$0.30

$0.315

1-Week Range:

$0.278

$0.33

52-Week Range:

$0.24

$1.31

Cara Therapeutics Inc Stock (CARA) Company Profile

Name

Cara Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

203-406-3700

Address

400 ATLANTIC STREET, SUITE 500, STAMFORD, CT

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CARA's Discussions on Twitter

Compare CARA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CARA	0.3102	17.11M	20.97M	-118.51M	-94.45M	-2.06
VRTX	447.61	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.94	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.97	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.87	24.49B	3.30B	-501.07M	1.03B	11.54

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jun-30-17	Downgrade	Janney	Buy → Neutral
Jun-30-17	Reiterated	Laidlaw	Buy
Jun-30-17	Reiterated	Stifel	Buy
Mar-28-17	Reiterated	H.C. Wainwright	Buy
Mar-28-17	Reiterated	Laidlaw	Buy
Mar-10-17	Reiterated	Laidlaw	Buy
Oct-13-16	Initiated	H.C. Wainwright	Buy
Aug-08-16	Reiterated	Needham	Buy

View All

Cara Therapeutics Inc Stock (CARA) Latest News

Nov 17, 2024

Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Stamford’s Cara Therapeutics continues financial struggles; 10-employee workforce down 91% - Hartford Business Journal

Nov 15, 2024